Metastasis is the leading cause of death in people with lung cancer, yet the molecular effectors underlying tumor dissemination remain poorly defined. Through the development of an in vivo spontaneous lung cancer metastasis model, we show that the developmentally regulated transcriptional repressor Capicua (CIC) suppresses invasion and metastasis. Inactivation of CIC relieves repression of its effector ETV4, driving ETV4-mediated upregulation of MMP24, which is necessary and sufficient for metastasis. Loss of CIC, or an increase in levels of its effectors ETV4 and MMP24, is a biomarker of tumor progression and worse outcomes in people with lung and/or gastric cancer. Our findings reveal CIC as a conserved metastasis suppressor, highlighting new anti-metastatic strategies that could potentially improve patient outcomes.
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide 1 . Metastasis accounts for >90% of NSCLCrelated deaths, yet its molecular basis remains poorly defined 2 . Models for studying metastasis have traditionally relied on experimental metastasis assays that directly introduce tumor cells into the circulation 3 . Although informative, these assays are influenced by tumor site injection and capture the later phases of metastasis 3 . Further limiting progress is the paucity of genetically engineered mouse models that rapidly develop spontaneous lung cancer metastasis 4 . Thus, the identification of genes necessary for tumor dissemination is hampered by the lack of tractable in vivo systems for rapid monitoring and functional dissection of spontaneous metastasis. We hypothesized that an orthotopic in vivo platform to monitor and mechanistically dissect NSCLC progression would lead to the identification of a novel molecular mediator of metastasis. Through coordinated use of this in vivo platform and analysis of human clinical specimens, we identified the transcriptional repressor CIC and its downstream effectors ETV4 and MMP24 as critical mediators, and clinical biomarkers, of lung and gastric adenocarcinoma progression and metastasis. Our findings establish a CIC-controlled metastatic cascade and uncover new potential anti-metastatic strategies that may improve clinical outcomes.
RESULTS

An in vivo orthotopic model identifies CIC as a mediator of metastasis
The in vivo orthotopic NSCLC system uses bioluminescence (BLI)based detection of implanted tumor cells and allows for direct visualization of primary tumor formation, circulatory tracking of tumor-derived cells, and development of macroscopic metastasis (Fig. 1a) . We initially studied epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LA) because EGFR-mutant LAs with an epithelial-to-mesenchymal transition can acquire hypermigratory properties in vitro that may reflect increased metastatic potential, concomitant with EGFR-inhibitor resistance [5] [6] [7] . But whether the molecular changes associated with the epithelial-tomesenchymal transition promote spontaneous metastasis and also underlie drug resistance is unclear. Reasoning that the in vivo system might provide insight into these questions, we used the existing EGFR-mutant LA system consisting of parental EGFR-inhibitor (rociletinib)-sensitive H1975 epithelial cells and two mesenchymal drug-resistant sublines (H1975 M1 and H1975 M2, previously called H1975 COR 10-1 and H1975 COR 1-1, respectively) independently derived from the parental population through prolonged rociletinib exposure 6 (Supplementary Fig. 1a ). In vitro analyses showed that these M1 and M2 sublines were hyperinvasive and maintained rociletinib resistance after drug washout, suggesting a stable molecular and phenotypic switch ( Supplementary Fig. 1b-d) .
Parental H1975 and H1975 M1 cells were engineered to express luciferase (Luc) and green fluorescent protein (GFP) and were directly implanted into the left lung of immunocompromised (SCID) mice using a surgical transpleural approach 8, 9 . Primary lung tumors were observed 3 d after implantation in ~70% of mice by BLI detection. Notably, 100% of H1975 M1-bearing mice developed mediastinal lymph node (LN) and contralateral lung metastasis within 2 weeks, compared to a 28% metastatic efficiency rate in the H1975 truncations, insertions, and a genomic deletion (deleterious events) ( Fig. 2a) . These clinical data suggest that CIC mutations are recurrent in tumors from advanced-stage LA patients, supporting a role for CIC in metastasis in addition to tumor proliferation.
We next engineered 11 CIC mutants selected from the advancedstage cohort to functionally interrogate in vitro and in vivo. These mutations were localized to the N terminus (G107E, R181W), the DNAbinding domain (Q247R), the repressor domain (R1515H, Q1516H), and an uncharacterized region between the DNA-binding and repressor domains (A281S, S649F, R666C, P722L, G1098D, and A1185T) (accession NM_015125.4). To assess the functional impact of these mutations on invasion, we expressed all 11 CIC mutants in H1975 M1 cells and carried out in vitro Transwell assays ( Fig. 2b, Supplementary Fig. 6a ). All CIC mutants tested were loss-of-function with respect to invasive potential, as these mutants were unable to suppress the hyperinvasive phenotype relative to wild-type CIC (Fig. 2c) . We next tested select CIC mutants in the orthotopic model and found that no mutant was able to suppress the hypermetastatic phenotype of H1975 M1 cells relative to wild type CIC ( Fig. 2d,e ). One mutant (G107E) exhibited a modest loss-of-function phenotype in vitro and in vivo compared with the other mutants tested. These data establish the loss-of-function phenotype of several CIC mutations identified in advanced-stage LA.
CIC has no established role in LA progression or metastasis, but it does have a crucial role in lung alveolarization, a developmental process regulated by extracellular matrix (ECM) remodeling 15, 16 . The mechanism by which CIC governs ECM maintenance may involve repression of the ETV4 transcription factor that promotes the expression of genes encoding matrix metalloproteinases (MMPs) 15, 17 (Fig. 2f) . We hypothesized that CIC loss de-represses ETV4, leading to augmented expression of genes involved in ECM remodeling, including those expressing MMPs, to promote invasion and metastasis ( Fig. 3a) . Indeed, we observed binding of CIC to the ETV4 promoter in both H1975 (endogenous CIC) and H1975 M1 (reconstituted CIC) cells ( Fig. 3b, Supplementary Fig. 6b ) with chromatin immunoprecipitation (ChIP)-PCR. We also detected de-repression of ETV4 in H1975 M1 and H1975 M2 cells ( Supplementary Fig. 6c ). To identify CIC-ETV4 metastasis-specific putative targets, we carried out a comparative transcriptome analysis of H1975 M1 and CIC-reconstituted H1975 M1 cells ( Supplementary Table 2 ). While we observed CIC-responsive differential expression of cell-cycle genes, we also observed enrichment in ECM-remodeling genes 18 (Supplementary  Fig. 5b,c) . We next compared the transcriptional profile of H1975 cells to those of H1975 M1 and H1975 M2 cells. Functional annotation (using DAVID) of the top 1,000 differentially expressed (DE) genes between H1975 cells and each metastatic subline showed enrichment in proteinaceous ECM genes (enrichment score (ES) = 8.36, P = 3.60 × 10 −10 for H1975 M1 cells; ES = 5.67, P = 3.20 × 10 −6 for H1975 M2 cells) ( Supplementary Table 3 ). Independent Gene Ontology (GO) analysis using GeneTrail supported enrichment for ECM genes (P = 1.63× 10 −9 for H1975 M1 cells, P = 4.02 × 10 −6 for H1975 M2 cells). Thus, we hypothesized that CIC regulates metastasis through a downstream ECM-remodeling program. In this way, CIC might engage distinct downstream pathways to preferentially drive different phenotypic responses, such as proliferation or metastasis. We reasoned that the orthotopic model would allow for discovery and functional validation of the CIC-responsive gene(s) that selectively drives cancer metastasis, without directly affecting tumor growth.
CIC represses ETV4-mediated MMP24 expression in LA
To identify a CIC-regulated metastasis effector, we investigated whether individual genes present in the ECM cluster correlated with clinical outcomes, using publically available mRNA data sets 19 . Of the 46 (H1975 M1) and 37 (H1975 M2) DE ECM genes in each subline, we selected the most highly upregulated genes shared between the two cell lines for analysis (SLC1A3, WNT5A, HAPLN1, COL8A1, and MMP24; an ADAMTS10 probe was not present) ( Supplementary  Fig. 6d ). Among the five candidate genes, only MMP24 upregulation (increased 24-fold in H1975 M1 cells and 11-fold in H1975 M2 cells) was significantly associated with worse progression-free survival (PFS) in patients with LN-positive NSCLC (N1; N = 130) ( Fig. 3c,  Supplementary Fig. 6e-h) . We observed a similar trend toward worse PFS in unselected NSCLC tumors with high MMP24 expression (N = 982, P = 0.069) ( Supplementary Fig. 6i ). As worse PFS can reflect metastatic progression, the data indicate that increased MMP24 expression in NSCLC identifies patients at high risk for tumor progression and worse outcomes. We further investigated MMP24 expression in two tissue microarrays (TMAs) containing 32 paired primary LAs and matched LN metastases. Basal MMP24 IHC staining was observed in primary tumors, and MMP24 expression was elevated upon metastasis in association with decreased CIC expression ( Fig. 3d,  Supplementary Fig. 6j-l) . Thus, the increased amount of MMP24 present in H1975 M1 and H1975 M2 cells is significantly and specifically associated with tumor progression and worse clinical outcome.
To investigate whether CIC regulates MMP24 via ETV4, we knocked down ETV4 in H1975 and H1975 M1 cells and subsequently observed decreased MMP24 levels ( Supplementary Fig. 7a ). We next identified three ETV4 binding elements (AGGAA) in the MMP24 promoter ( Supplementary Fig. 7b ). ChIP-PCR in H1975 M1 cells showed MMP24 promoter occupancy by ETV4, and promoter A r t i c l e s assays showed that ETV4 overexpression increased MMP24 activity ( Supplementary Fig. 7c,d ), suggesting that ETV4 regulates MMP24 expression. We next established stable CIC knockdown in H1975 cells using three independent hairpins (shCICa-c). CIC knockdown led to increased expression of ETV4 and MMP24 ( Fig. 3e) , which enhanced metastatic efficiency compared with controls ( Fig. 3f,g) . Ex vivo imaging showed contralateral metastasis in mice bearing CIC-knockdown cells (Supplementary Fig. 7e ). Thus, CIC loss is sufficient to enhance LA metastasis. In contrast to our observations with CIC reconstitution, which suppressed H1975 M1 cell growth, we did not note an increase in tumor growth with CIC knockdown ( Supplementary  Fig. 7f,g) . These data suggest that different thresholds of CIC expression and transcriptional modulation of its target genes may regulate the distinct functional outputs that CIC controls.
In further support of this CIC-ETV4-MMP24 axis, CIC reconstitution in H1975 M1 cells led to decreased invasion and decreased levels of ETV4 and MMP24 ( Fig. 3h,i, Supplementary Fig. 7h ). Decreased invasiveness was directly linked to MMP24, as MMP24 re-expression in CIC-expressing H1975 M1 cells rescued the invasive phenotype ( Fig. 3i, Supplementary Fig. 7i ). Consistent with this, CIC-mediated suppression of H1975 M1 cell metastasis in vivo (Fig. 1g ) was associated with decreased MMP24 expression in tumors ( Supplementary  Fig. 7j,k) . Interestingly, CIC re-expression did not restore rociletinib sensitivity, suggesting that CIC controls metastatic potential but not EGFR-inhibitor sensitivity (Supplementary Fig. 7l ). Thus, CIC regulates ETV4 and MMP24 to control metastatic capacity in LA.
MMP24 is a multistep effector of lung cancer metastasis
MMP24 is a membrane-type MMP with no known role in metastasis, but it promotes neuronal migration 20 . We hypothesized that MMP24 is necessary and sufficient for lung cancer invasion and metastasis. We observed increased MMP24 expression in H1975 M1 and H1975 M2 cells, and we then carried out MMP24 knockdown with two distinct short hairpin RNAs (shRNAs) (shMMP24a and shMMP24b) ( Supplementary Fig. 8a,b ). MMP24 silencing reduced invasion and metastasis without affecting primary tumor implantation or growth ( Fig. 4a,b, Supplementary Fig. 8c-h) . Numbers of CTCs were reduced in MMP24-knockdown mice compared to controls ( Fig. 4c) . Further, MMP24 expression was localized to the leading edge of primary tumors in H1975 M1 mice, consistent with an invasiveness-driving function (Fig. 4d) . Immunofluorescence using tumor-specific markers (GFP and human-specific vimentin) showed EV  R666C  P722L  G1098D  A1185T  R1515H  Q1516H  R181W  Q247R  A281S  S649F  WT  G107E   CIC   HSP90   H1975 M1   1  267 704 439 441 600 459 493 397 367 560 366 P29fs*24  A62S  G107E × 2  P113S  G133S  P165L  R181W  Q247R   P722L  P775L  S739*  S914L  A927V  Q940H  T1005A  V1038L   G1049C  G1098D  T1103_S1104insPAPT  P1107T  A1185T  S1191_F1192insK  R1214G  R1256Q  G1280V   D1456V  S1461C  R1515H  Q1516H  T1525M  A1533V that these MMP24-expressing cells were tumor derived and invading into mouse lung ( Fig. 4e) . These data suggest that MMP24 confers a capacity for invasiveness to promote tumor dissemination from the primary site.
We next determined whether MMP24 is sufficient to promote extravasation and colonization. We overexpressed MMP24 in weakly metastatic H1975 cells (Supplementary Fig. 8i ) and assessed lung colonization using a tail vein assay 21 . Both H1975 and H1975 MMP24overexpressing cells reached the pulmonary circulation at day 1 ( Supplementary Fig. 8j,k) . However, by day 21 pulmonary luminescence in the control mice was nearly undetectable ( Supplementary  Fig. 8k) , indicating that the cells were incapable of stable colonization. In contrast, pulmonary luminescence in mice harboring cells overexpressing MMP24 persisted throughout the 21-d period ( Supplementary Fig. 8j,k) . Thus, MMP24 promotes tumor-cell circulatory extravasation and stable lung colonization.
MMP24 was also sufficient to augment spontaneous metastasis, as MMP24 overexpression in H1975 cells increased invasion and promoted tumor dissemination to metastatic sites, including bone, in the orthotopic system ( Fig. 4f-i, Supplementary Fig. 8l-n) . MMP24 overexpression did not confer a growth advantage in H1975 cells (Supplementary Fig. 8o ). Thus, our in vivo molecular dissection identified CIC, its downstream effector ETV4, and its target MMP24 as joint multi-step mediators of metastasis and suggests that the functional effectors downstream of CIC that regulate metastasis or proliferation may be distinct. Fig. 9a ), suggesting that CIC-mediated metastasis is uncoupled from EGFR-inhibitor resistance. Thus, we examined whether MMP24 controls metastasis more broadly in LA. Assessment of baseline invasiveness in treatment-naive human LA cells showed that A549 and HCC364 cells were highly invasive ( Supplementary Fig. 9b ). MMP24 silencing suppressed invasion in A549 and HCC364 cells ( Supplementary Fig. 10a,b,h,i) . Moreover, MMP24 knockdown was linked to reduced MMP24-mediated proteolytic activity, as MMP24 silencing decreased cleavage of N-cadherin (CDH2) (a known MMP24 substrate) in A549 cells ( Supplementary  Fig. 9c ), suggesting that MMP24 may enhance pericellular invasion via proteolysis of adhesion proteins 22 .
MMP24 promotes metastasis across multiple NSCLC models MMP24 overexpression did not confer rociletinib resistance in H1975 cells (Supplementary
We used the orthotopic system to assess whether MMP24 promotes metastasis in A549 and HCC364 cells. Whereas 100% of mice in the A549 and HCC364 control groups developed spontaneous metastasis within 1 week, MMP24 knockdown reduced tumor metastasis without affecting growth ( Fig. 4j,k, Supplementary Fig. 10c ,j-l). Persistent MMP24 suppression and absence of Luc activity in the contralateral lung in non-metastatic mice was confirmed by IHC and ex vivo BLI assay in A549 and HCC364 mice ( Supplementary  Fig. 10d,e,m,n) . Numbers of CTCs were reduced after MMP24 silencing in A549 and HCC364 mice, most prominently in mice without metastasis ( Supplementary Fig. 10f,o) . In A549 and HCC364 MMP24knockdown mice that developed metastasis, MMP24 expression A r t i c l e s was detected in a subpopulation of cells at the primary site, suggesting that certain cells either escaped initial MMP24 silencing or re-activated MMP24 after its initial knockdown ( Supplementary  Fig. 10g,p) . We next studied an EGFR L858R patient-derived xenograft (PDX) from a patient with metastatic LA 23 . IHC analysis of the PDX showed robust MMP24 staining (Supplementary Fig. 11a ). When the PDX was orthotopically implanted, we observed overt primary tumor formation and spontaneous metastasis to the contralateral lung ( Fig. 4l) . Moreover, we found a functional role for MMP24 in promoting metastasis in our PDX, as MMP24 knockdown decreased invasion by tumor cells derived from this EGFR L858R PDX (Fig. 4m,   Supplementary Fig. 11b,c) . Our data suggest that the CIC-ETV4 downstream effector MMP24 promotes metastasis across multiple LA models.
Functional suppression of CIC de-represses ETV4-MMP24
To determine whether CIC expression correlates with LA progression, we performed CIC IHC analysis in a human lung TMA 24 . We found decreased nuclear CIC expression in LA specimens (stage I-III; n = 130) compared with normal tissue (n = 126), which correlated with increased MMP24 expression in these tumors ( Fig.  5a, Supplementary Fig. 12a-c) . Using NSCLC mRNA data sets 19 , A r t i c l e s we observed an association between worse PFS and specifically unselected patient tumors with high levels of ETV4 compared to those with low ETV4 expression ( Fig. 5b, Supplementary Fig. 12d) . Additionally, we observed a positive correlation between ETV4 and MMP24 in the TCGA LA data set (Supplementary Fig. 12e ). Interestingly, we did not observe a correlation between decreased CIC mRNA and either ETV4 or MMP24 mRNA expression in these data sets, suggesting an alternative mode of CIC regulation beyond transcriptional control. Given this finding, coupled with a low frequency of CIC genetic alterations in LA, we investigated whether CIC levels are post-translationally regulated. Indeed, CIC can be functionally suppressed via post-translational modification whereby ERK phosphorylates nuclear CIC to promote nuclear export and degradation and thereby relieve repression of CIC target genes [25] [26] [27] (Fig. 5c) . As most LAs (~60-70%) harbor genetic alterations that hyperactivate ERK 28 , we reasoned that ERK-mediated post-translational suppression of CIC may de-repress ETV4-MMP24 in cancers with genetically intact CIC. Because growth factor stimulation can promote ERK-mediated CIC suppression [25] [26] [27] , we monitored nuclear CIC expression with time-lapse microscopy in H1975 M1 cells expressing CIC-GFP during epidermal growth factor (EGF)-stimulated ERK activation. GFP-tagged CIC was expressed in the nucleus at baseline, and this expression decreased after EGF stimulation (Fig. 5d) . We did not observe cytoplasmic accumulation but did note a rapid decrease in CIC protein expression upon ERK activation ( Fig. 5e, Supplementary Fig. 13a) . In concordance, we found that proteasome inhibition with bortezomib or MEK inhibition with trametinib could rescue EGF-mediated CIC degradation (Fig. 5f,g, Supplementary Fig. 13b,c) . Additionally, inhibition of ERK signaling with rociletinib increased CIC activity and reduced ETV4 promoter activity, leading to decreased ETV4 and MMP24 expression in H1975 cells (Fig. 5h,i) . Reciprocally, EGF stimulation of serum-starved H1975 cells resulted in decreased CIC expression ( Supplementary Fig. 13d) . Moreover, ERK inhibition with trametinib augmented CIC expression and decreased ETV4 expression, MMP24 expression, and invasion in KRAS-mutant A549 cells, without affecting growth (Supplementary Fig. 13e-g) . These data suggest that ERKmediated CIC suppression de-represses the ETV4-MMP24 axis to enhance metastasis in LAs with hyperactive MAPK signaling, augmenting the role of CIC in NSCLC progression beyond those tumors with genetically altered CIC.
The CIC-ETV4-MMP24 metastatic axis is engaged in GA Analysis of TCGA tumors identified a high frequency of CIC alterations in gastric adenocarcinoma (GA). We found that 26% (75/287) of GA cases harbored CIC genetic alterations (homozygous deletion (n = 3) + nonsense/frameshift/missense mutation (26 tumors with 29 total mutations) + hemizygous loss (n = 46)) 29 (Fig. 6a) . Consistent with a functional role for CIC inactivation in the promotion of tumor progression, deleterious CIC alterations (truncations and homozygous deletions) were more frequently observed in advanced-stage GA (Fig. 6b) .
To correlate CIC expression with GA progression, we assessed nuclear CIC expression in 84 human GA specimens (stage I (n = 15), stage II (n = 54), or stage III (n = 15)) and 80 normal tissues. Decreased CIC expression correlated with GA progression (Fig. 6c, Supplementary  Fig. 14a) . To test whether CIC loss promotes aggressive metastatic gastric cancer progression, we studied publically available mRNA data sets, and we found that specifically advanced-stage patients with low CIC expression had worse overall survival 30 (Fig. 6d, Supplementary  Fig. 14b,c) . Thus, decreased CIC may promote lethal metastatic GA progression. We further investigated whether CIC loss was linked A r t i c l e s to increased levels of ETV4 and MMP24 in gastric cancer. Indeed, expression of ETV4 and MMP24 was increased in tumors with CIC copy number (CN) loss in the TCGA data set 29 (Fig. 6e,f) . Although we did not identify a correlation between ETV4 or MMP24 and survival in stage IV GA patients, high ETV4 and/or MMP24 expression was more broadly implicated as a biomarker of worse outcomes across all GA stages (Fig. 6g,h, Supplementary Fig. 14d-g) . Additionally, we studied GA TMAs and found increased MMP24 expression in LN metastases compared to primary tumors (Supplementary Fig. 14h,i) .
Collectively, the data suggest that the CIC-ETV4-MMP24 axis we uncovered in LA may also regulate GA progression.
As the function of CIC and whether it controls ETV4 and MMP24 in GA are unknown, we overexpressed CIC in AGS cells (harboring CIC F780S ) and found that this suppressed the ETV4-MMP24 axis (Supplementary Fig. 14j,k) . CIC overexpression decreased invasion, and re-expression of MMP24 in CIC-overexpressing AGS cells restored invasiveness (Fig. 6i) . CIC overexpression did not suppress GA growth (Supplementary Fig. 14l) . Further, the pro-invasive function of MMP24 is conserved in GA, as MMP24 knockdown decreased invasion but not tumor growth ( Fig. 6j, Supplementary Fig. 14m,n) . These data indicate a context-specific role for CIC in GA progression and metastasis, and they suggest that genetic or post-translational suppression of CIC can de-repress the pro-metastatic ETV4-MMP24 axis across cancer subtypes.
Conserved dysregulation of CIC targets in LA and GA
We hypothesized that there may be a shared set of CIC-responsive genes in LA and GA. We first identified 1,844 downregulated genes in H1975 M1 cells upon CIC rescue (adjusted P < 10 × 10 −10 ; Supplementary Fig. 15a) . A promoter survey of these 1,844 genes identified 267 putative CIC targets that contained the CIC binding motif (T(G/C)AATG(G/A)A) ( Supplementary Fig. 15a,  Supplementary Table 4 ). We investigated whether GAs and LAs with CIC inactivation harbored increased levels of these putative CIC targets. We defined a set of CIC-responsive genes by stratifying TCGA GA tumors into two groups-CIC CN loss and CIC CN neutral-and identified 163 DE genes (absolute log 2 fold change > 0.79, false discovery rate (FDR) < 0.10) (Supplementary Fig. 15a) . Because MAPKsignaling-mediated suppression of CIC seems to be a predominant mode of CIC inactivation in LA, we stratified TCGA LAs by KRAS mutant versus KRAS wild-type, which yielded 79 DE genes (absolute log 2 fold change > 0.79, FDR < 0.10) (Supplementary Fig. 15a ). Comparative analysis of the DE genes from GA and LA tumors identified ETV4 as a conserved CIC-responsive gene ( Supplementary  Fig. 15a ). Thus, ETV4 seems to be a CIC target across GA (CIC genetic loss) and LA (post-translational CIC suppression). Finally, we analyzed >4,700 tumors across 12 different tumor types and found that increased ETV4 expression correlated with worse survival in tumors with CIC CN loss 31 (Supplementary Fig. 15b,c) . The data suggest convergent inactivation of CIC and consequent activation of its effector, ETV4, across distinct cancer subtypes.
DISCUSSION
We established an in vivo orthotopic model to study spontaneous NSCLC metastasis and identified CIC as a suppressor of tumor progression and metastasis. Our study establishes the utility of the orthotopic system for molecular dissection of mediators of spontaneous metastasis in vivo. We show that lung and gastric cancers suppressed CIC to gain tumor-cell-autonomous, MMP24-dependent metastatic competence. Our data identify CIC, ETV4, and MMP24 as biomarkers of clinical progression and provide a rationale for therapeutic strategies that could augment CIC or block ETV4-MMP24 to suppress metastasis.
Beyond genetic inactivation, ERK-mediated suppression of CIC may promote metastasis by augmenting the ETV4-MMP24 axis (Fig. 7) . Hence, the widespread MAPK pathway hyperactivation present in LA may, in part, explain the high and rapid metastatic propensity of NSCLC. Pharmacologic inhibition of MAPK signaling may suppress metastasis by restoring CIC-mediated repression of the effectors ETV4 and MMP24 in tumors with genetically intact CIC. These anti-metastatic effects of MAPK pathway blockade may be distinct from, or occur in addition to, effects on cell growth. Our findings provide motivation to further explore the interplay between MAPK signaling and CIC function across cancer subtypes. Overall, our study offers mechanistic insight into the molecular basis of metastasis and highlights new strategies to identify, monitor, and therapeutically block metastatic progression.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
Orthotopic lung xenografts in immunodeficient mice. Six-to eight-weekold female SCID CB.17 mice were purchased from Taconic (Germantown, NY). Specific-pathogen-free conditions and facilities were approved by the American Association for Accreditation of Laboratory Animal Care. Surgical procedures were reviewed and approved by the UCSF Institutional Animal Care and Use Committee (IACUC), protocol #AN107889-02B.
To prepare cell suspensions for thoracic injection, we briefly trypsinized adherent tumor cells, quenched them with 10% FBS RPMI media, and resuspended them in PBS. Cells were pelleted again and mixed with Matrigel matrix (BD Bioscience, 356237) on ice to achieve a final concentration of 1.0 × 10 5 cells/µl. The Matrigel cell suspension was transferred into a 1-ml syringe and remained on ice until the time of implantation.
For orthotopic injection, mice were placed in the right lateral decubitus position and anesthetized with 2.5% inhaled isoflurane. A 1-cm surgical incision was made along the posterior medial line of the left thorax. Fascia and adipose tissue layers were dissected and retracted to expose the lateral ribs, the intercostal space, and the left lung parenchyma. Upon recognition of left lung respiratory variation, a 30-gauge hypodermic needle was used to advance through the intercostal space ~3 mm into the lung tissue. For human cancer cell lines, care was taken to inject 10 µl (1.0 × 10 6 cells) of cell suspension directly into the left lung. For PDX orthotopic xenotransplantation, a single-cell suspension was first prepared after whole-tumor explant from the flanks of immunodeficient mice. Whole tumors were washed in PBS, minced with a sterile scalpel, incubated at 37 °C in trypsin for 15 min, and triturated with a 25-gauge syringe until cells could easily pass through the needle bore. The PDX cell suspension was washed with PBS, resuspended in Matrigel, and then aspirated into a 30-gauge syringe, and 10 µl was injected into the left lung. The needle was rapidly withdrawn, and mice were observed for pneumothorax. Visorb 4/0 polyglycolic acid sutures were used for primary wound closure of the fascia and skin layer. Mice were observed post-procedure for 1-2 h, and their body weights and wound healing were monitored weekly 9 .
In vivo bioluminescence imaging. Mice were imaged at the UCSF Preclinical Therapeutics Core starting on post-injection day 7 with a Xenogen IVIS 100 bioluminescent imaging system. Prior to imaging, mice were anesthetized with isoflurane and injected intraperitoneally (IP) with 200 µl of D-Luciferin at a dose of 150 mg per kg body weight. Weekly monitoring of BLI of the engrafted lung tumors was performed until week 5. Radiance was calculated automatically using Living Image Software following demarcation of the thoracic cavity in the supine position. The radiance unit of photons/s/cm 2 /sr is the number of photons per second that leave a square centimeter of tissue and radiate into a solid angle of one steradian (sr).
to data for H1975 derivative lines M1 and M2, using RSEM 33 . Similarly, the H1975 M1 transcriptome was also compared to that for H1975 M1 with CIC reconstitution to obtain CIC-responsive genes. Genes were ranked according to significance of differential expression between parental and derived lines using DESeq.
Functional annotation and clustering was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID). The top 1,000 differentially expressed genes between the H1975 parental line and H1975 M1 or H1975 M2 were used to derive two independent gene lists. Both lists were entered into DAVID to generate two independent functional clustering lists with associated enrichment P values 34 . GeneTrail GO analysis was performed using the same 1,000 differentially expressed genes between parental H1975 and H1975 M1 or H1975 M2. GeneTrail GO analysis was performed using the top 1,500 differentially expressed genes between H1975 M1 and H1975 M1 with CIC reconstitution 35 .
Copy number segmentation of parental and derived exomes from pairedend DNA-seq data was performed using CNVkit 36 .
The Cancer Genome Atlas data analysis. Mutational analysis was performed using the cBio Cancer Genomics Portal 37 . Lung (n = 521) and stomach (n = 287) adenocarcinoma data sets were used to search for mutations and copy number variations in the CIC gene. Using the cBio lung and stomach adenocarcinoma data sets, we identified CIC frameshift and nonsense mutations and manually verified the clinical stage for each TCGA specimen. Mutation analyses of advanced, metastatic lung adenocarcinomas (n = 1,342) were obtained from Foundation Medicine.
CIC, ETV4, and MMP24 correlative expression analysis. Data preparation.
TCGA RNA-seq RSEM (v2) gene expression measurements were downloaded from the Firehose portal on 28 August 2015. Stomach/gastric cancer samples were unavailable from Firehose and were instead downloaded from the TCGA DCC portal. We calculated the transcripts-per-million expression values used in the analysis by multiplying every gene's scaled estimate by 10 6 . The data set was quantile-normalized to minimize potential batch effects. Gistic2 discretized copy number calls were downloaded from the Firehose portal on 27 May 2014.
Expression analysis. Expression levels of MMP24 and ETV4 after normalization were compared between patient samples with either single or double copy number loss for CIC to patients with copy number neutral CIC. P values were calculated using a Mann-Whitney-Wilcoxon rank sum test comparing the expression values in patient samples with copy loss to the copy number neutral samples.
Analysis of copy number alteration in H1975, H1975 M1, and H1975 M2 cells. Copy number alterations were first generated from Control-FREE Copy Number Caller (Control-FREEC) using the normalized distribution of reads to determine differences in coverage of whole exome sequence between normal and H1975, H1975 M1, or H1975 M2 cells (ref. 38) . We then used the previously published Shiny application (https://malinost.shinyapps.io/CNPupload) to visualize Control-FREEC profiles 39 . The Shiny program uploaded the ratios from the Control-FREEC file and allowed direct visualization through R-based chromosome plots. Once H1975, H1975 M1, or H1975 M2 Control-FREEC files had been uploaded into the Shiny application, we set the parameters to achieve visualization of chromosome 19 with a range set to optimally locate CIC (chromosome 19 position 42,772,689-42,799,949 in human GRCH37/hg19).
Establishment of CIC-responsive gene set. Gene expression quantification
from paired-end RNA-seq data was performed on H1975 M1 CIC-null cells and compared to H1975 M1 cells with CIC reconstitution using RSEM 33 . Genes were ranked according to significance of differential expression using DESeq. 1,844 significantly downregulated genes (adjusted P value < 10 × 10 −10 ) were identified and subsequently surveyed for the CIC binding consensus sequence (T(G/C)AATG(G/A)A) in the promoter region (−2,000 to +100 bp relative to the transcription start site); sequences were downloaded from the eukaryotic promoter database (http://epd.vital-it.ch/).
CIC mutation analysis in early-and advanced-stage lung adenocarcinoma.
For CIC-mutation identification in the TCGA, we used the lung adenocarcinoma provisional data set to identify early-stage (I-II) and advanced-stage (III-IV) tumors. A total of five patients (TCGA-69-7980-01, TCGA-97-7547-01, TCGA-64-5779-01, TCGA-75-6214-01, and TCGA-86-8056-01) were identified among 488 patients with clinical-stage and CIC mutational analysis available.
For the Rizvi cohort, we used the cBio portal to identify tumors with mutations in CIC, JB112852 and ZA6965.
Differential expression of lung and gastric adenocarcinoma TCGA data sets. The normalized gene expression TCGA data sets for lung adenocarcinoma (LUAD_exp_HiSeqV2_PANCAN-2015-02-24) and stomach adenocarcinoma (TCGA_STAD_exp_HiSeq-2015-02-24) along with stomach somatic copy number data (TCGA_STAD_gistic2_thresholded-2015-02-24) were downloaded from the UCSC Cancer Genomics Browser. For lung cancer, the samples were stratified into KRAS mutation and KRAS wild-type subgroups; for stomach cancer, samples were stratified into CIC loss and CIC normal subgroups; samples with CIC gain were excluded from analysis. The Limma R package was used for differential gene expression analysis; significantly differentially expressed genes between these two subgroups were generated with absolute log 2 fold change greater than 0.79 and FDR (Benjamini-Hochberg adjustment) less than 0.1 cutoff.
Differential expression and survival analysis of the pan-cancer TCGA data set. The pan-cancer TCGA data set (TCGA_PANCAN12_copynumber-2015-01-28) was downloaded from the UCSC Cancer Genomics Browser. Pan-cancer samples were stratified into CIC loss and CIC normal subgroups; samples with CIC gain were excluded from analysis. Samples in each subgroup were then stratified on the basis of ETV4 expression level.
To correlate ETV4 expression with overall survival in the pan-cancer data set, we computed the median ETV4 expression level across all samples. Samples with expression above the median were defined as ETV4 high, and those with expression below the median as ETV4 low. A log-rank test was used to establish a P value in the Kaplan-Meier (KM) overall survival curve.
Lung and gastric cancer survival analysis. KM curves for lung and gastric cancer overall survival and time to first progression (PFS) were generated using the Kaplan-Meier Plotter database 19, 30 The 'recommended' MMP24 probe (213171_s_at) was used to generate all KM plots. To identify LN-positive NSCLC patients in our study, we selected AJCC stage N1 patients for analysis. We used the 2015 version gene symbol MMP24 probe 213171_s_at, survival FP (first progression) (n = 982), autoselect best cutoff, all histology selected, AJCC stage N1 (n = 130). HAPLN1 probe 205523_at, WNT5A probe 213425_at, COL8A1 probe 214587_at, and SLC1A3 probe 202800_at were used to generate NSCLC KM plots with AJCC stage N1 patients as done for MMP24. No ADAMTS10 probe was available for survival analysis. For 'all comers' analysis in NSCLC (n = 982) we used the following parameters: gene symbol MMP24 probe 213171_s_at, survival FP, autoselect best cutoff, all histology selected, AJCC stage all (N = 982). For ETV4 in NSCLC we used the following selection criteria: KM plotter 2015 version, gene symbol ETV4 probe 211603_s_at, survival FP, auto-select best cutoff, all histology selected (N = 982); and gene symbol ETV4 probe 211603_s_at, survival FP, auto-select best cutoff, all histology selected, AJCC stage N1 (N = 130).
For gastric cancer analyses and generation of PFS and overall survival KM survival curves we used the 'recommended' MMP24 probe 213171_at_s, ETV4 probe 211603_s_at, and CIC probe 212784_s_at. For MMP24, ETV4, and CIC analyses in gastric cancer, all parameters were left at default settings with auto-selection of the best cutoff for analysis. Stage IV patients with poorly differentiated gastric cancer were selected in an independent analysis of CIC, ETV4, and MMP24; all other settings were left as default with auto-selection of best cutoffs.
Statistical analysis. Experimental data are presented as mean ± s.e.m. P values derived for all in vitro experiments were calculated by either two-tailed Student's t-test or one-way ANOVA. KM metastasis-free survival curves were calculated using the log-rank test.
For each in vivo experiment, including orthotopic studies, 10-15 mice were injected with each specified cell line as indicated, and all were included in the
